BioVaxys Technology Corp.
BVAXF · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | $134 | $963 | $726 |
| G&A Expenses | $2,392 | $2,112 | $2,661 | $3,533 |
| SG&A Expenses | $3,121 | $2,269 | $2,835 | $5,253 |
| Sales & Mktg Exp. | $422 | $157 | $174 | $1,720 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3,122 | $2,403 | $4,082 | $6,442 |
| Operating Income | -$3,122 | -$2,403 | -$3,803 | -$5,979 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$833 | -$5,285 | -$7,925 | -$479 |
| Pre-Tax Income | -$3,955 | -$7,687 | -$11,727 | -$6,458 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,955 | -$7,687 | -$11,727 | -$6,458 |
| % Margin | – | – | – | – |
| EPS | -0.202 | -0.573 | -1.2 | -0.779 |
| % Growth | 64.7% | 52.3% | -54% | – |
| EPS Diluted | -0.202 | -0.573 | -1.2 | -0.779 |
| Weighted Avg Shares Out | 19,572 | 13,415 | 9,818 | 8,293 |
| Weighted Avg Shares Out Dil | 19,572 | 13,414 | 9,818 | 8,293 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $25 | $16 | $8 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3,122 | $2,403 | $3,803 | -$439 |
| EBITDA | $0 | $0 | $0 | -$6,418 |
| % Margin | – | – | – | – |